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Abstract
Background
Core outcome sets (COS) comprise a minimum set of outcomes that should be measured
and reported in all trials for a specific health condition. The COMET (Core Outcome Mea-
sures in Effectiveness Trials) Initiative maintains an up to date, publicly accessible online
database of published and ongoing COS. An annual systematic review update is an impor-
tant part of this process.
Methods
This review employed the same, multifaceted approach that was used in the original review
and the previous two updates. This approach has identified studies that sought to determine
which outcomes/domains to measure in clinical trials of a specific condition. This update
includes an analysis of the inclusion of participants from low and middle income countries
(LMICs) as identified by the OECD, in these COS.
Results
Eighteen publications, relating to 15 new studies describing the development of 15 COS,
were eligible for inclusion in the review. Results show an increase in the use of mixed meth-
ods, including Delphi surveys. Clinical experts remain the most common stakeholder group
involved. Overall, only 16% of the 259 COS studies published up to the end of 2016 have
included participants from LMICs.
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Conclusion
This review highlights opportunities for greater public participation in COS development and the
involvement of stakeholders from a wider range of geographical settings, in particular LMICs.
Introduction
Measuring appropriate outcomes in clinical trials enables the benefits and harms of specific
treatments to be compared between trials and allows decision makers, such as patients and cli-
nicians, to be best informed in their choice. This is known as comparative effectiveness
research (CER) [1]. Heterogeneity of outcome reporting in trials is, however, common, even
in trials exploring the effects of the same intervention on a specific disease [2]. The lack of
comparability that results from this causes waste in research [3,4]. This waste could be avoided
with the development and systematic use of core outcome sets (COS) in clinical trials research,
as demonstrated by the uptake in trials of a COS developed in rheumatoid arthritis [5]. A COS
represents an agreed minimum set of outcomes that should be measured and reported in all
trials for a specific health condition [2]. An element of the scope of the COS, to be defined, is
whether the COS is to be applicable to all interventions or exclusively to specific intervention
types. The use of COS would ensure all trials produce evidence that can be combined appro-
priately with the results of other trials, while not restricting the researchers’ ability to explore
other, additional outcomes [2].
The purpose of the COMET (Core Outcome Measures in Effectiveness Trials) Initiative is
to encourage the development, promotion and application of COS across all health areas. It
does so by maintaining an up-to-date, online, publicly-accessible database of ongoing and
published COS studies. Three systematic reviews have comprehensively searched for COS; the
original review, conducted in 2013 [6], and two updates, one conducted in 2015 [7] and the
second conducted in 2016 [8].
The 2016 update showed that COS had been developed for 13 of the world’s 25 most preva-
lent health conditions, leaving 12 of the 25 as being in need of COS development [8]. Eighty-
two percent of the COS applicable to the world’s most prevalent health conditions involved
participants from Europe and North America only. International participation in COS was
highlighted as a key research gap. Representation of stakeholders from Africa and South
America was particularly low in comparison to other continents, at only one and three studies
(respectively). Further research is needed to establish how COS can be developed to have the
greatest global relevance and applicability to the global burden of disease.
Aims
The aims of the current study were to (i) update the systematic review [6–8] in order to iden-
tify any further studies where a COS has been developed; (ii) to describe the methodological
approaches taken in these studies, (iii) to identify countries in which COS development partic-
ipants are located and (iv) to highlight areas for future COS development and improvement.
Methods
Systematic review update
The methods used in this updated review followed the same approach used in the original
review and in the previous two updates [6–8].
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Study selection.
Inclusion and exclusion criteria: As described in detail previously [6], studies were eligible
for inclusion if they developed or applied methodology for determining which outcome
domains or outcomes should be measured, or are important to measure, in clinical trials or
other forms of health research. As noted in the 2016 update [8], by using the term ‘outcome’
we are referring to something that occurs as a result of the specific health condition (e.g. diar-
rhoea) and by ‘outcome domain’ we are referring to the grouping of individual outcomes (e.g.
bowel function, which would include diarrhoea).
Types of participants and interventions: As described previously [6], studies were catego-
rised as eligible if they reported the development of a COS, regardless of any restrictions by
age, health condition or setting, which could be used to assess the effect of interventions for
that condition.
Identification of relevant studies. In March 2017, we searched MEDLINE via Ovid and
SCOPUS (including EMBASE) without language restrictions. The search identified studies
that had been published or indexed between the previous systematic review update [8] in Janu-
ary 2016 and the end of December 2016. The multifaceted search strategy, developed for the
original review using a combination of text words and index terms and combining three con-
cepts of search terms that cover ‘randomised trial’, ‘systematic review’, ‘methodology’ and ‘out-
comes’ [9] was used in the current update, with adaptations appropriate for each database (S1
Table). The search was deferred until March 2017 due to indexing issues that had been identi-
fied with the previous reviews [8], namely that studies published at the end of a particular year
of interest had not been indexed in the database until the beginning of the following year and
hence were not captured by the database search. We searched in March for this update to try
to overcome this limitation. In addition to this database searching, we also completed hand
searching activities as previously described [8]. We identified any studies that had been sub-
mitted directly to the COMET database. We also examined references cited in eligible studies
and in ineligible studies that referred to or used a COS.
Selecting studies for inclusion in the review. Records from each database were combined
and duplicates were removed. Titles and abstracts were read to assess eligibility of studies for
inclusion in the review (stage 1). Full texts of potentially relevant articles were obtained to
assess for inclusion (stage 2). Titles and abstracts were divided between reviewers (KD, NH,
VS and PRW) who independently checked the title and abstract of each citation assigned to
them and classified them as include, exclude or unsure. Where there was uncertainty in the
classification of a record, a second reviewer was consulted. If agreement could not be achieved,
the citation was referred to a fifth reviewer (SG). Full papers were divided between three
reviewers (KD, NH and VS) for full-paper review. Reasons for exclusion at this stage were doc-
umented for articles judged to be ineligible.
Checking for agreement between the reviewers. During each stage of the review process,
agreement between reviewers was assessed. Prior to independently assessing records, the four
reviewers (KD, NH, VS and PRW) independently checked batches of abstracts and full papers
to confirm consistency. This was repeated in batches of 10 until complete agreement was
reached in three consecutive batches.
Checking for correct exclusion. Of the records that had been excluded on the basis of the
title and abstract, full text papers were obtained for a 1% sample and a fifth reviewer (SG)
assessed correct exclusion. If any studies were identified as being incorrectly excluded, further
checking was performed within the other excluded records. Of the records that had been
excluded after reading their full text papers, 5% were assessed for correct exclusion at that
stage. In this review, no studies were excluded incorrectly.
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Data extraction. As described in detail previously [6], data were extracted in relation to
the study aim(s), health area, target population, interventions covered, methods of COS devel-
opment and stakeholder groups involved. Data relating to the geographical locations of partici-
pants included in the development of COS were extracted for studies found in the current
update, as was done in the previous reviews.
Data analysis and results. As previously [6], we used a narrative analysis and the results
are presented descriptively. The results were analysed for the scope of their aims, intended use,
population characteristics and intervention characteristics. The methods used, and stakehold-
ers involved in selecting outcomes were also analysed. This update also included an analysis of
the inclusion of participants from low and middle income countries (LMICs), as identified by
the OECD, in these COS.
Results
Description of studies
Following the removal of duplicates, 4406 citations were identified in the database search. A total
of 3887 records were excluded during the title and abstract stage, and a further 503 were excluded
following the assessment of full text papers (Fig 1). Table 1 provides a summary of the reasons for
exclusion of papers at abstract and full text stage. Sixteen citations relating to 13 new studies met
the inclusion criteria. In addition to the database search, two additional citations were identified
as being eligible for inclusion in the review. In total, 18 reports relating to 15 new studies describ-
ing the development of 15 COS were added to the review during this update (S2 Table).
Three of the reports included in this updated are linked to COS studies that were reported in
previous reviews [6,7]. One report is linked to a previously published preliminary COS, which has
since been modified and endorsed [10]. Two further reports are linked to previously published
COS, which have been revised to meet the current standards of outcome measure development
[11,12]. All updates and revisions reported in the linked papers are reflected in the tables below.
Included studies
Year of publication. Our analysis of the year of first publication of each COS study
included in the previous reviews has been updated to include the 15 new studies identified in
this updated review (Fig 2). Of the 15 studies discussed here, 13 studies were published in 2015
or 2016, and two studies were published in 2014. Two studies were identified through refer-
ence checking of a COS study. One of these studies had been excluded from a previous review
at the title and abstract screening stage because of the lack of COS information in the abstract
[13]. The other study was identified through reference checking of related COS studies and
had not come up in any of the previous review searches [14]. As referred to by the study
authors, the scope of this COS, specifically the health condition, overlaps with earlier COS.
Scope of core outcome sets. The scope of published COS studies is summarised in Table 2
and includes 259 COS studies (describing the development of 309 COS) that were included in
the three previous systematic reviews and the 15 new COS studies that have been added by this
updated review. Please see S2 Table in supplementary material for the scope of the disease cate-
gories and names relevant to each of the 15 new COS. During this update, five studies that were
judged to be COS in previous reviews were reviewed and excluded [15–19]. One was retrospec-
tively deemed to refer to how to measure outcomes rather than what to measure [18] and four
others were deemed to be composite end points rather than core outcome sets [15–17,19].
Methods used to select outcomes. The methods used to develop the 15 new COS are pre-
sented in Table 3 alongside the methods used in the combined reviews [6–8]. The results show
an increase in the use of mixed methods, including Delphi surveys.
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Stakeholders involved in selecting outcomes. Table 4 lists the stakeholders that were
involved in selecting outcomes for inclusion in the COS identified in this update and the com-
bined reviews. Regarding the 259 published COS studies, 225 have provided details about the
stakeholders who participated in the development process. Of these 225 studies, clinical
experts have been involved in selecting outcomes for inclusion in 222 (99%) studies; this con-
trasts with public representatives, who have been included in only 62 (28%) studies.
Public representatives include patients, carers, health and social care service users and peo-
ple from organisations who represent these groups. The degree of public participation within
the development of the COS studies included in this updated review is described in Table 5.
Seven of the eight studies that reported including public participants, provided details about
their participation. Among studies that report public participation, levels of participation
range from 15% [20] to 66% [21]. Where patients are involved, they tend to make up a greater
percentage of the participants than in COS reported in previous reviews.
Countries involved in the development of COS
Table 6 lists the geographical locations, by continent, of the participants involved in developing
the COS in this update and in the combined reviews, as reported by the included studies.
Fig 1. Identification of studies.
https://doi.org/10.1371/journal.pone.0190695.g001
Table 1. Reasons for exclusion at full text stage.
Exclusion Categories of Full Text Stage Number of
Papers
Studies relating to how, rather than which, outcomes should be measured 21
Studies reporting the design/ rationale of single trial 1
Studies reporting the use of a COS 2
Systematic reviews of clinical trials 13
Systematic review of prognostic studies 2
Review/overview/discussion only, no outcome recommendations 37
Core outcomes/ outcome recommendations not made 63
Quality indicators–structure and/or process of care only 10
One outcome/ domain only 3
Instrument development 4
Recommendations by single author only 1
ICF Core set 0
Describes features of registry 9
Preclinical/ Early phase only (0, I, II) 5
Quantitative description 1
Value attributed to outcomes 0
Irrelevant 271
Assessed in previous review 0
Systematic review of outcomes used in studies 12
HRQL 3
Recommendations for clinical management in practice not research 31
Studies that elicit stakeholder group opinion regarding which outcome domains or outcomes
are important
10
Ongoing studies 4
https://doi.org/10.1371/journal.pone.0190695.t001
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Fig 3 displays a choropleth map of the world, which uses differences in shading to indicate
the number of COS studies that have been developed with the inclusion of participants from
each country. Of the 259 COS studies published by the end of 2016, the countries which have
been most involved in the COS development process are the United States of America (USA)
(n = 161) and the United Kingdom (UK) (n = 124). There are 93 countries which are displayed
on the map in the lightest shading; these represent the locations that have not been included in
the development of any COS.
Of the 259 published COS studies, 41 (16%) have included participants from low and mid-
dle income countries (LMICs). These LMICs were identified according to the Organization
for Economic Co-operation and Development (OECD) Development Assistance Committee
(DAC) list of Official Development Assistance (ODA) recipients [22]. Table 7 presents a
breakdown of the LMICs that have been involved in the development of COS.
Discussion
This update to the previous three COMET Initiative systematic reviews has identified 18 publi-
cations relating to 15 new COS, suggesting that COS continue to be developed and published.
A range of resources are available on the COMET website to facilitate COS development.
These include a core resource pack, plain language summaries and information about how to
optimise the involvement of parents, young people and patient organisations in COS studies.
This work has now been brought together in the COMET Handbook [23] to provide guidance
on the development, application and implementation of COS.
Fig 2. Year of first publication of each COS study (n = 259).
https://doi.org/10.1371/journal.pone.0190695.g002
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Table 2. The scope of included studies (n = 259).
Update review 3 n (%) Combined
n (%)
Study aims
Specifically considered outcome selection and measurement 10 (60) 142 (54)
Considered outcomes while addressing wider clinical trial design issues 5 (40) 117 (46)
Intended use of recommendations
Clinical research 9 (60) 226 (87)
Clinical research and practice 6 (40) 33 (13)
Population characteristics
Adults 6 (40) 36 (14)
Children 0 (0) 30 (12)
Adults and children 8 (53) 25 (10)
Older adults 0 (0) 3 (1)
Adolescents and young adults 1 (7) 1 (<1)
Not specified 0 (0) 164 (63)
Intervention characteristics
All intervention types 8 (53) 39 (15)
Drug treatments 0 (0) 42 (16)
Surgery 4 (27) 25 (10)
Vaccine 0 (0) 2 (<1)
Rehabilitation 1 (7) 3 (1)
Exercise 0 (0) 3 (1)
Procedure 0 (0) 6 (2)
Device 1 (7) 4 (1)
Other 1 (7) 17 (7)
Not specified 0 (0) 118 (46)
https://doi.org/10.1371/journal.pone.0190695.t002
Table 3. The methods used to develop COS (n = 259).
Main methods Update review 3 n (%) Combined n (%)
Semi-structured group discussion only 59 (23)
Unstructured group discussion only 18 (7)
Consensus development conference only 13 (5)
Literature/systematic review only 1 (7) 19 (7)
Delphi only 10 (4)
Survey only 3 (1)
NGT only 1 (<1)
Mixed methods (see descriptions below)1 12 (80) 116 (45)
Delphi + another method(s) 9 (60) 48 (19)
Semi-structured group discussion + another method(s) 2 (13) 42 (16)
Consensus development conference + another method(s) 7 (3)
Literature/systematic review + another method(s) 1 (7) 14 (5)
NGT + another method(s) 4 (2)
Focus group + another method(s) 1 (<1)
No methods described 2 (13) 20 (8)
1 Mixed methods studies are reported cumulatively. For example if they have been included in one subcategory they
will be excluded from subsequent categories even if they apply.
https://doi.org/10.1371/journal.pone.0190695.t003
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Of the 259 COS studies published up to the end of 2016, the USA and the UK continue to
be the most frequently represented countries by stakeholders involved. Use of the COMET
website is continuing to increase, with the number of visitor locations reaching 175 countries
in 2017 [24], however there are 96 countries that have not been included in the development
of any COS. COS developed with globally rather than nationally located participants might
improve the global applicability of clinical trials. To be comprehensive, a COS should be
Table 4. Participant groups involved in selecting outcomes for inclusion in COS (n = 225).
Participants category Sub-category (not mutually exclusive) Frequency of participants
Update review 3
n (%)1
Combined
n (%)2
Clinical experts 14 (93) 222 (99)
Clinical experts 14 131 (58)
Clinical research expertise 2 87 (39)
Clinical trialists/Members of a clinical trial network 11 (5)
Others with assumptions 54 (24)
Public representatives 8 (53) 62 (28)
Patients 8 45 (20)
Carers 3 14 (6)
Patient support group representatives 15 (7)
Service users 1 3 (1)
Non-clinical research experts 2 (13) 73 (32)
Researchers 2 37 (16)
Statisticians 26 (12)
Epidemiologists 14 (6)
Academic research representatives 4 (2)
Methodologists 11(5)
Economists 4 (2)
Authorities 0 47 (21)
Regulatory agency representatives 37 (16)
Governmental agencies 13 (6)
Policy makers 5 (2)
Charities 1 (<1)
Industry representatives 0 38 (17)
Pharmaceutical industry representatives 34 (15)
Device manufacturers 3 (1)
Biotechnology company representatives 1 (<1)
Others 1 (7) 76 (34)
Ethicists 1 (<1)
Journal editors 3 (1)
Funding bodies 1 (<1)
Yoga therapists/instructors 1 (<1)
Members of health care transition research consortium 1 1 (<1)
Others (besides known participants) 15 (7)
Others with assumptions 54 (24)
No details given 0 (0) 34 (15)
1Studies providing details about participants groups involved in selecting outcomes (n) = 15
2Studies providing details about participants groups involved in selecting outcomes (n) = 225
https://doi.org/10.1371/journal.pone.0190695.t004
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applicable in all relevant settings, including across different countries where appropriate. COS
are more likely to be applicable within those countries that the participants in the development
process are from. Therefore, if a COS is intended to have international applicability, this
would have implications for how it is developed, who is involved, and the resources required
for the development process. In particular, the developers should involve participants from
countries where the prevalence or burden of the disease is high, but, with this in mind, it is
worth noting that only 16% of COS developed to date have included participants from LMICs.
Table 5. Public participation detail where reported (n = 7).
Methods used Total number of participants Number of public participants % Public participants
1 Delphi (clinician only) Round 1: 75 Round 1: 0
Round 2: 48 Round 2: 0
Delphi (mixed)1 Round 3: 61 Round 3: 24 39%
Meeting (mixed) 16 2 15%
2 Delphi (mixed) Round 1: 258 Round 1: 90 35%
Round 2: 200 Round 2: 80 40%
Round 3: 173 Round 3: 71 41%
Meeting (clinician only) 33 0
Meeting (patient only) 9 9
3 Meeting (clinician only) 16 0
Survey (clinician only) 16 0
Survey (patient only) 0 221
4 Delphi (mixed) Round 1: 228 Round 2: 150 66%
Round 2: 208 Round 2: 135 65%
5 Delphi (mixed) Round 1: 115 Round 1: 55 48%
Round 2: 101 Round 2: 46 46%
Round 3: 86 Round 3: 35 41%
6 Delphi (mixed) Round 1: 195 Round 1: 97 50%
Round 2: 165 Round 2: 87 53%
Meeting (clinician only)2 61 0
35 0
Meeting (patient only) 14 14
7 Survey (patient only) 615 615
1Patients brought in at round 3.
2 A second clinician meeting was held as consensus was not reached within the allotted time during the first clinician meeting
 Patient core set
https://doi.org/10.1371/journal.pone.0190695.t005
Table 6. Geographical locations of participants included in the development of each COS (n = 214).
Continents Update review 3
n (%)
Combined
n (%)
North America 6 (55) 167 (78)
Europe 10 (91) 167 (78)
Australasia 3 (27) 56 (26)
Asia 1 (9) 45 (21)
South America 1 (9) 24 (11)
Africa 1 (9) 15 (7)
No details provided 4 (27) 45 (17)
https://doi.org/10.1371/journal.pone.0190695.t006
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Furthermore, COS developed with participants from multiple countries might improve the
global applicability of the COS and, consequently, the global relevance and impact of the clini-
cal trials that these are used in. A survey has recently been undertaken to identify the top prior-
ities for trials methodological research in LMICs to inform further research and ultimately to
improve clinical trials in these regions. The priority most commonly graded as critically
important, amongst 400 participants from over 80 countries, was choosing appropriate out-
comes to measure [25].
Fig 3. Number of COS studies that have included participants from each individual country throughout the world.
https://doi.org/10.1371/journal.pone.0190695.g003
Table 7. OECD DAC list of ODA recipient countries involved in the COS development process.
DAC1 list
classifications
Number of COS
involving participants
Countries
Least Developed
Countries
4 Afghanistan, Burkina Faso, Ethiopia, Gambia, Liberia, Malawi,
Mali, Mozambique, Nepal, Senegal, Tanzania
Other Low Income
Countries
3 Kenya, Zimbabwe
Lower Middle Income
Countries
17 Cameroon, Egypt, Georgia, Ghana, Guatemala, India,
Indonesia, Morocco, Nigeria, Pakistan, Philippines, Sri Lanka,
Ukraine
Upper Middle Income
Countries
39 Albania, Algeria, Argentina, Brazil, Chile, China, Colombia,
Costa Rica, Cuba, Ecuador, Iran, Lebanon, Malaysia, Mexico,
Panama, Peru, Serbia, South Africa, Thailand, Tunisia, Turkey,
Uruguay, Venezuela
1 Development Assistance Committee
https://doi.org/10.1371/journal.pone.0190695.t007
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Implications
The 15 new COS studies have been added to the COMET database, ensuring that it will remain
up to date and continue to assist trialists, researchers, clinicians and others to design clinical
trials, guidelines and systematic reviews. It will also remain a key source of information for
those looking to develop a COS. Although reporting has improved, use of the COS-STAR
guideline [26] will help further.
The updated review reported here highlights a continuing need to involve participants
from a greater range of geographical locations in COS development, particularly from LMICs,
in order to increase the global relevance of COS.
Limitations
Gathering accurate data on the geographic location of participants is dependent on the report-
ing of this information, which was provided for over 70% of the COS studies in this review
update. It is possible that there could be more COS involving participants from LMICs than
reported here, although, there is no obvious reason why those reporting geographic informa-
tion may differ with respect to LMIC involvement.
The abstracts reviewed in this study were reviewed by a single author only, in contrast to
previous reviews where two reviewers reviewed each abstract. It is conceivable that some COS
may have been missed at this stage of screening, however checks have been put in place to min-
imise incorrect exclusion, including batch checks and additional reviewers checking samples
of excluded studies. The impact of this lack of identification on the usefulness of the COMET
database is minimised, as the annual systematic review update is only one of a number of
methods used to populate the COMET database, which also include database alerts and direct
contact with COS developers throughout the year.
Conclusions
In conclusion, this study has demonstrated the continuing development of new COS. The
results show an increase in the use of mixed methodologies for COS development but suggest
a need to push for greater public participation and the involvement of stakeholders from a
broader range of countries, in particular LMICs. These efforts will increase the applicability of
COS to global health and tackling the global burden of disease.
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